852469-69-3

Upstream product

• 1253787-57-3 4-bromo-3-(pentafluoro-λ⁶-sulfanyl)aniline 
• 852469-55-7 2-(4-nitro-3-pentafluorsulfanyl-phenyl)-isoindol-1,3-dione 
• 2993-22-8 3-pentafluorosulfuraniline 
• 2613-26-5 3-nitrophenylsulfur pentafluoride 
• 64-17-5 ethanol 

Downstream Products

• 1006898-89-0 4-(4,4-dimethyl-2,5-dioxoimidazolidin-1-yl)-2-pentafluorosulfanylbenzonitrile 

Relevant academic research and scientific papers

CEREBLON BINDING COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH

Provided herein are piperidine dione compounds having the following structure: wherein R1, R2, R3, R4, L, V, X, A, A′, a and m are as defined herein, compositions comprising an effective amount of a piperidine dione compound, and methods for treating or preventing an androgen receptor mediated disease.

CEREBLON BINDING COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH

Provided herein are piperidine dione compounds having the following structure: wherein RN, R1, R2, R3, R4, RN, L, V, X, a, m, and n are as defined herein, compositions comprising an effective amount of a piperidine dione compound, and methods for treating or preventing an androgen receptor mediated disease.

Synthesis of aryl propionamide scaffold containing a pentafluorosulfanyl moiety as SARMs

The pentafluorosulfane (SF5) group, as a more electronegative bioisostere than the trifluoromethyl (CF3) group, has been gaining greater attention and increasingly reported usage in medicinal chemistry. Ostarine is the selective androgen receptor modulators (SARMs) containing a CF3 group in clinical trial III. In this study, 21 ostarine derivatives for replacing the CF3 group with SF5 substituents were synthesized. Some SF5-derivatives showed androgen receptor (AR) agonistic activities in vitro. The results pointed to the potential of using this scaffold to develop new AR agonists.

Synthesis of androgen receptor antagonists containing a pentafluorosulfanyl (SF5) moiety

A novel scaffold of pentafluorosulfanyl (SF5)-containing enzalutamide analogues was discovered for potent androgen receptor (AR) antagonists through rational drug design. Several compounds showed good biological profiles in AR binding. Of the derivatives studied, compound 8a had potent AR antagonist activity (IC50 = 7.1 ± 1.0 μM) and high efficacy (104.5 ± 12.8%). It exhibited an inhibitory effect comparable to that of enzalutamide (inhibition = 66.0 and 77.9%, respectively) in a prostate cancer cell line. The results point to the potential of using this scaffold to develop new AR antagonists.

TRIAZOLE COMPOUNDS AS ANTIVIRALS

The present invention discloses compounds of Formula I: wherein the variables in Formula I are defined as described herein. Also disclosed are pharmaceutical compositions containing such compounds and methods for using the compounds of Formula I in the prevention or treatment of HCV infection.

Substituted imidazoline-2,4-diones, process for preparation thereof, medicaments comprising these compounds and use thereof

The invention relates to compounds of formula (I) wherein the groups R and R′, A, D, E, G, L, p and R1 to R10 have the stated meanings and to their physiologically compatible salts. Said compounds are suitable, for example, as anti-obesity drugs.

Arylaminoaryl-alkyl-substituted imidazolidine-2,4-diones, process for preparing them, medicaments comprising these compounds, and their use

This invention relates to arylaminoaryl-alkyl-substituted imidazolidone-2,4-diones of formula (I) and also to their physiologically tolerated salts: Wherein R, R′, R1 to R10, A, D, E, G, L and p are as defined herein. The invention also relates to processes for preparing them, pharmaceutical compositions comprising them and their therapeutic use. The compounds are suitable, for example, as anti-obesity drugs and for treating cardiometabolic syndrome.

ORTHO-SUBSTITUTED PENTAFLUORIDE SULFANYL-BENZENES, METHOD FOR THE PRODUCTION THEREOF AND THE USE THEREOF IN THE FORM OF VALUABLE SYNTHESIS INTERMEDIATE STAGES

The invention relates to pentafluoride-sulfanyl-benzenes of formula (I), wherein groups from R1 to R5 correspond to meanings given in claims and constitute valuable intermediates, for example for producing drugs, diagnosis agents, liquid crystals, polymers, herbicides, fungicidals, nematicidals, parasiticides, insecticides, acaricides and arthropodicides.